Ipamorelin

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone releasing peptide (GHRP) family. Unlike natural growth hormone or its releasing hormone analogues, ipamorelin was specifically designed to trigger growth hormone release through the ghrelin receptor pathway while avoiding the unwanted side effects typically associated with other GHRPs [1]. Developed in the late 1990s by Novo Nordisk, it represents what researchers call a "selective" GHRP.\n\nWhat makes ipamorelin distinct from other peptides in this class is its selectivity profile. While compounds like GHRP-6 and hexarelin stimulate not only growth hormone but also cortisol and prolactin release, ipamorelin primarily targets growth hormone with minimal impact on these other hormones [2]. This selective action has made it a subject of research interest for applications where you want the benefits of increased GH without the complications of elevated stress hormones.\n\nThe peptide works by mimicking ghrelin, the "hunger hormone," but in a more targeted way. Research facilities have used ipamorelin to study growth hormone physiology because it produces a clean, pulsatile GH release pattern that closely resembles natural circadian rhythms [3]. This controlled release pattern is why researchers consider it useful for studying GH-related processes without the confounding variables introduced by other peptides.